April 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountimfinzi.com
Global Rank
#824,898
181,960Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
60.65%
Pages per Visit
1.64
Avg Visit Duration
00:01:11
- Company
- - -
- Industry
- - -
Top 10 imfinzi.com Competitors
The Top 10 Sites Like imfinzi.com in April 2026 are ranked by their affinity to imfinzi.com in terms of keyword traffic, audience targeting, and market overlap
Find helpful TAGRISSO® (osimertinib) resources for you and your patients including downloads, copay, and insurance information, or contact a representative.
- Company
- - -
- Industry
- - -
Global Rank
#1,584,058
602,253Bounce Rate
58.17%
Pages per Visit
1.52
Avg Visit Duration
00:00:19
Similarity Score
100%The RYBREVANT® (amivantamab-vmjw) Official Healthcare Website. See Full Prescribing and Safety Information.
- Company
- - -
- Industry
- - -
Bounce Rate
63.91%
Pages per Visit
1.43
Avg Visit Duration
00:00:08
Similarity Score
97%The RYBREVANT® (amivantamab-vmjw) Official Patient Website. See Full Prescribing and Safety Information.
- Company
- - -
- Industry
- - -
Global Rank
#2,117,753
496,729Bounce Rate
75.26%
Pages per Visit
1.18
Avg Visit Duration
00:00:20
Similarity Score
96%learn about tagrisso® (osimertinib), a targeted treatment option for people with certain types of egfr+ non-small cell lung cancer (nsclc). talk to your doctor to see if tagrisso is right for you.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
65.9%
Pages per Visit
1.29
Avg Visit Duration
00:02:16
Similarity Score
93%health care professionals may find information about fda-approved indications for keytruda® (pembrolizumab) along with keynote clinical trials and treatment guidelines.
- Company
- - -
- Industry
- - -
Global Rank
#848,382
16,581Bounce Rate
65.15%
Pages per Visit
1.22
Avg Visit Duration
00:00:18
Similarity Score
91%See Important Safety Information and Prescribing Information.
- Company
- - -
- Industry
- - -
Bounce Rate
88.44%
Pages per Visit
1.16
Avg Visit Duration
00:00:31
Similarity Score
90%See risks & benefits. BRAFTOVI® (encorafenib) in combination with cetuximab can be used as an Rx treatment in adults with previously treated BRAF+ V600E metastatic CRC.
- Company
- - -
- Industry
- - -
Bounce Rate
75.82%
Pages per Visit
1.33
Avg Visit Duration
00:01:28
Similarity Score
89%CABOMETYX® (cabozantinib) is a multi-indication cancer treatment FDA-approved for 1L & 2L aRCC, 2L HCC and 2L DTC. See Important Safety Information.
- Company
- - -
- Industry
- - -
Bounce Rate
80.42%
Pages per Visit
1.25
Avg Visit Duration
00:00:06
Similarity Score
88%Find answers to frequently asked questions about VYLOY® and advanced stomach cancer. Please see full Prescribing Information.
- Company
- - -
- Industry
- - -
Bounce Rate
92.69%
Pages per Visit
1.08
Avg Visit Duration
00:00:04
Similarity Score
87%Find tips for caregivers of loved ones taking PADCEV®. Please see full Patient Information, including Serious Side Effects.
- Company
- - -
- Industry
- - -
Global Rank
#752,635
264,186Bounce Rate
77.43%
Pages per Visit
1.60
Avg Visit Duration
00:01:08
Similarity Score
86%imfinzi.com's top 5 competitors in April 2026 are: tagrissohcp.com, rybrevanthcp.com, rybrevant.com, tagrisso.com, and more.
According to Similarweb data of monthly visits, imfinzi.com’s top competitor in April 2026 is tagrissohcp.com. imfinzi.com 2nd most similar site is rybrevanthcp.com, and closing off the top 3 is rybrevant.com.
tagrisso.com ranks as the 4th most similar website to imfinzi.com and keytrudahcp.com ranks fifth in April 2026.
The other five competitors in the top 10 list are ninlarohcp.com, braftovi.com, cabometyxhcp.com, vyloy.com, and padcev.com.